Subtype
Early Stage Breast Carcinoma
CI-CAN-00002563Explore in graph →
57 active trials2 approved drugs
- NCIt
- C94774
Loading cancer entity…
Subtype
CI-CAN-00002563Explore in graph →
Clinical trials
145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (13)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00309478 | Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients | completed | Phase 3 | 1,099 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 0 | Jun 29, 2023 | clinicaltrials |
| NCT04109391 | Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 | completed | Phase 3 | 338 | Tanvex BioPharma USA, Inc.INDUSTRY | 10 | Oct 26, 2022 |
| NCT00309491 | Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients | completed | Phase 3 | 2,021 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 0 | Oct 19, 2020 | clinicaltrials |
| NCT00309569 | Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients | completed | Phase 3 | 429 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 0 | Oct 14, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jun 29, 2023source: clinicaltrials